{"id":"NCT03374488","sponsor":"Incyte Corporation","briefTitle":"Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma","officialTitle":"A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-22","primaryCompletion":"2018-07-27","completion":"2020-07-23","firstPosted":"2017-12-15","resultsPosted":"2019-08-28","lastUpdate":"2025-08-22"},"enrollment":84,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["UC (Urothelial Cancer)"],"interventions":[{"type":"DRUG","name":"Pembrolizumab","otherNames":["MK-3475"]},{"type":"DRUG","name":"Epacadostat","otherNames":["INCB024360"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pembrolizumab 200 mg + Epacadostat 100 mg BID","type":"EXPERIMENTAL"},{"label":"Pembrolizumab 200 mg + placebo BID","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a first-line platinum-containing chemotherapy regimen for advanced/metastatic disease.","primaryOutcome":{"measure":"Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo","timeFrame":"up to 9 weeks +14 days","effectByArm":[{"arm":"Pembrolizumab 200 mg + Epacadostat 100 mg BID","deltaMin":21.4,"sd":null},{"arm":"Pembrolizumab 200 mg + Placebo BID","deltaMin":9.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":135,"countries":["United States","Australia","Canada","Denmark","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Netherlands","Russia","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39054485"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":42},"commonTop":["Anaemia","Constipation","Decreased appetite","Fatigue","Nausea"]}}